Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence

PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
InsomniaAlcohol Use Disorder
Interventions
DRUG

Suvorexant 20 mg

Placebo controlled double blind suvorexant vs placebo

OTHER

placebo

Placebo controlled double blind suvorexant vs placebo

Trial Locations (1)

3065

St Vincent's Hospital, Melbourne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

St Vincent's Hospital Melbourne

OTHER

collaborator

Melbourne Health

OTHER

lead

The Florey Institute of Neuroscience and Mental Health

OTHER